Insmed, Inc. (INSM): Price and Financial Metrics

Insmed, Inc. (INSM): $21.62

0.09 (+0.42%)

POWR Rating

Component Grades













Add INSM to Watchlist
Sign Up

Industry: Biotech



in industry


  • INSM scores best on the Value dimension, with a Value rank ahead of 71.55% of US stocks.
  • The strongest trend for INSM is in Growth, which has been heading down over the past 179 days.
  • INSM ranks lowest in Momentum; there it ranks in the 5th percentile.

INSM Stock Summary

  • INSMED INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 2.11% of US listed stocks.
  • INSM's price/sales ratio is 12.04; that's higher than the P/S ratio of 90.35% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 8.16 for INSMED INC; that's greater than it is for 87.16% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to INSMED INC are CYTK, MRNS, FBIO, LXRX, and SPCE.
  • Visit INSM's SEC page to see the company's official filings. To visit the company's web site, go to

INSM Valuation Summary

  • In comparison to the median Healthcare stock, INSM's price/sales ratio is 457.14% higher, now standing at 11.7.
  • Over the past 243 months, INSM's price/earnings ratio has gone down 5.9.

Below are key valuation metrics over time for INSM.

Stock Date P/S P/B P/E EV/EBIT
INSM 2023-01-30 11.7 -94.8 -6.5 -7.9
INSM 2023-01-27 12.1 -98.1 -6.8 -8.1
INSM 2023-01-26 12.0 -97.0 -6.7 -8.1
INSM 2023-01-25 12.1 -97.6 -6.7 -8.1
INSM 2023-01-24 12.1 -97.6 -6.7 -8.1
INSM 2023-01-23 11.9 -96.4 -6.6 -8.0

INSM Growth Metrics

    Its 3 year price growth rate is now at -18.61%.
  • The 3 year cash and equivalents growth rate now stands at 22.72%.
  • Its 2 year cash and equivalents growth rate is now at 20.23%.
INSM's revenue has moved up $105,715,000 over the prior 33 months.

The table below shows INSM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 242.182 -381.422 -434.389
2022-06-30 221.209 -367.039 -415.958
2022-03-31 201.354 -340.182 -437.634
2021-12-31 188.461 -363.302 -434.654
2021-09-30 173.752 -345.962 -423.889
2021-06-30 170.638 -329.185 -374.834

INSM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INSM has a Quality Grade of C, ranking ahead of 31.6% of graded US stocks.
  • INSM's asset turnover comes in at 0.172 -- ranking 207th of 682 Pharmaceutical Products stocks.
  • CYRX, CTLT, and ACOR are the stocks whose asset turnover ratios are most correlated with INSM.

The table below shows INSM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.172 0.760 -0.609
2021-06-30 0.192 0.753 -0.585
2021-03-31 0.209 0.754 -0.551
2020-12-31 0.206 0.757 -0.513
2020-09-30 0.215 0.776 -0.415
2020-06-30 0.214 0.795 -0.422

INSM Price Target

For more insight on analysts targets of INSM, see our INSM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.78 Average Broker Recommendation 1.4 (Strong Buy)

INSM Stock Price Chart Interactive Chart >

Price chart for INSM

INSM Price/Volume Stats

Current price $21.62 52-week high $28.94
Prev. close $21.53 52-week low $16.41
Day low $21.09 Volume 764,400
Day high $21.96 Avg. volume 1,456,671
50-day MA $19.54 Dividend yield N/A
200-day MA $21.13 Market Cap 2.93B

Insmed, Inc. (INSM) Company Bio

Insmed Incorporated is a biopharmaceutical company focused on developing targeted inhaled therapies for patients suffering from rare lung diseases. The company was founded in 1999 and is based in Bridgewater, New Jersey.

INSM Latest News Stream

Event/Time News Detail
Loading, please wait...

INSM Latest Social Stream

Loading social stream, please wait...

View Full INSM Social Stream

Latest INSM News From Around the Web

Below are the latest news stories about INSMED INC that investors may wish to consider to help them evaluate INSM as an investment opportunity.

Wall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade

The mean of analysts' price targets for Insmed (INSM) points to a 98.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | January 24, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

Yahoo | January 20, 2023

The past five years for Insmed (NASDAQ:INSM) investors has not been profitable

The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have...

Yahoo | January 19, 2023

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company's four pillars and outlined its near-term strategic priorities. These updates will be discussed as part of the Company's presentation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2023, at 4:30 p.m. PT (7:30 p.m. ET).

Yahoo | January 6, 2023

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 41st Annual J.P. Morgan Healthcare…

PR Newswire | January 3, 2023

Read More 'INSM' Stories Here

INSM Price Returns

1-mo 12.72%
3-mo 18.79%
6-mo -22.09%
1-year -3.05%
3-year -25.14%
5-year -18.69%
YTD 8.21%
2022 -26.65%
2021 -18.17%
2020 39.41%
2019 82.01%
2018 -57.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7578 seconds.